Oncogenic Role of HER3

CME

Deciphering HER3: Biologic Underpinnings, Expression Patterns, and Oncogenic Role

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: December 31, 2024

Expiration: June 30, 2025

Activity

Progress
1 2
Course Completed

Introduction 

In this module, Zofia Piotrowska, MD, MHS, discusses the role of HER3 in the ERBB/HER family and its potential role in oncogenesis, as suggested by its expression patterns in non-small-cell lung cancers (NSCLCs) and after prior treatment with EGFR tyrosine kinase inhibitors (TKIs). Therapeutic strategies to target HER3 currently in development are also summarized.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many people with lung cancer do you provide care for in a typical week? 

Which of the following statements about HER3 is correct?